TrialNeuro-oncology2023

Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.

Andrea M Gross et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.